|
Gene: IFI27 |
Gene summary for IFI27 |
Gene summary. |
Gene information | Species | Human | Gene symbol | IFI27 | Gene ID | 3429 |
Gene name | interferon alpha inducible protein 27 | |
Gene Alias | FAM14D | |
Cytomap | 14q32.12 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A8K0H0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3429 | IFI27 | GSM4909281 | Human | Breast | IDC | 3.10e-136 | 1.91e+00 | 0.21 |
3429 | IFI27 | GSM4909282 | Human | Breast | IDC | 7.31e-08 | 3.76e-01 | -0.0288 |
3429 | IFI27 | GSM4909285 | Human | Breast | IDC | 3.06e-05 | 3.84e-01 | 0.21 |
3429 | IFI27 | GSM4909287 | Human | Breast | IDC | 1.81e-51 | 1.30e+00 | 0.2057 |
3429 | IFI27 | GSM4909288 | Human | Breast | IDC | 4.22e-09 | 1.03e+00 | 0.0988 |
3429 | IFI27 | GSM4909290 | Human | Breast | IDC | 1.60e-66 | 1.55e+00 | 0.2096 |
3429 | IFI27 | GSM4909294 | Human | Breast | IDC | 1.65e-06 | 4.77e-01 | 0.2022 |
3429 | IFI27 | GSM4909297 | Human | Breast | IDC | 5.88e-03 | 4.21e-01 | 0.1517 |
3429 | IFI27 | GSM4909307 | Human | Breast | IDC | 9.24e-100 | 1.71e+00 | 0.1569 |
3429 | IFI27 | GSM4909308 | Human | Breast | IDC | 7.77e-108 | 1.76e+00 | 0.158 |
3429 | IFI27 | GSM4909309 | Human | Breast | IDC | 3.93e-44 | 1.27e+00 | 0.0483 |
3429 | IFI27 | GSM4909315 | Human | Breast | IDC | 1.60e-123 | 1.94e+00 | 0.21 |
3429 | IFI27 | GSM4909316 | Human | Breast | IDC | 6.23e-29 | 1.62e+00 | 0.21 |
3429 | IFI27 | GSM4909317 | Human | Breast | IDC | 7.85e-55 | 1.42e+00 | 0.1355 |
3429 | IFI27 | GSM4909318 | Human | Breast | IDC | 7.18e-38 | 1.99e+00 | 0.2031 |
3429 | IFI27 | GSM4909320 | Human | Breast | IDC | 5.69e-05 | 8.56e-01 | 0.1575 |
3429 | IFI27 | GSM4909321 | Human | Breast | IDC | 2.07e-160 | 2.15e+00 | 0.1559 |
3429 | IFI27 | M1 | Human | Breast | IDC | 4.51e-38 | 1.26e+00 | 0.1577 |
3429 | IFI27 | M2 | Human | Breast | IDC | 5.13e-07 | 9.94e-01 | 0.21 |
3429 | IFI27 | NCCBC5 | Human | Breast | DCIS | 3.41e-85 | 1.81e+00 | 0.2046 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005116824 | Oral cavity | EOLP | nuclear export | 47/2218 | 154/18723 | 4.45e-10 | 3.76e-08 | 47 |
GO:004682222 | Oral cavity | EOLP | regulation of nucleocytoplasmic transport | 37/2218 | 106/18723 | 4.85e-10 | 4.04e-08 | 37 |
GO:000020923 | Oral cavity | EOLP | protein polyubiquitination | 62/2218 | 236/18723 | 7.88e-10 | 5.90e-08 | 62 |
GO:004316125 | Oral cavity | EOLP | proteasome-mediated ubiquitin-dependent protein catabolic process | 92/2218 | 412/18723 | 9.87e-10 | 6.96e-08 | 92 |
GO:006033721 | Oral cavity | EOLP | type I interferon signaling pathway | 23/2218 | 50/18723 | 1.93e-09 | 1.26e-07 | 23 |
GO:007135721 | Oral cavity | EOLP | cellular response to type I interferon | 23/2218 | 52/18723 | 4.98e-09 | 2.74e-07 | 23 |
GO:003434021 | Oral cavity | EOLP | response to type I interferon | 24/2218 | 58/18723 | 1.17e-08 | 5.55e-07 | 24 |
GO:000961521 | Oral cavity | EOLP | response to virus | 81/2218 | 367/18723 | 1.71e-08 | 7.66e-07 | 81 |
GO:001905826 | Oral cavity | EOLP | viral life cycle | 72/2218 | 317/18723 | 3.11e-08 | 1.24e-06 | 72 |
GO:001907925 | Oral cavity | EOLP | viral genome replication | 38/2218 | 131/18723 | 9.10e-08 | 3.15e-06 | 38 |
GO:009719125 | Oral cavity | EOLP | extrinsic apoptotic signaling pathway | 54/2218 | 219/18723 | 9.74e-08 | 3.36e-06 | 54 |
GO:001922112 | Oral cavity | EOLP | cytokine-mediated signaling pathway | 94/2218 | 472/18723 | 2.36e-07 | 7.37e-06 | 94 |
GO:004682522 | Oral cavity | EOLP | regulation of protein export from nucleus | 13/2218 | 30/18723 | 1.48e-05 | 2.46e-04 | 13 |
GO:000661123 | Oral cavity | EOLP | protein export from nucleus | 19/2218 | 57/18723 | 1.70e-05 | 2.79e-04 | 19 |
GO:005160721 | Oral cavity | EOLP | defense response to virus | 55/2218 | 265/18723 | 2.16e-05 | 3.35e-04 | 55 |
GO:014054621 | Oral cavity | EOLP | defense response to symbiont | 55/2218 | 265/18723 | 2.16e-05 | 3.35e-04 | 55 |
GO:004440325 | Oral cavity | EOLP | biological process involved in symbiotic interaction | 57/2218 | 290/18723 | 7.75e-05 | 9.39e-04 | 57 |
GO:001603233 | Oral cavity | NEOLP | viral process | 101/2005 | 415/18723 | 1.08e-15 | 5.85e-13 | 101 |
GO:004682231 | Oral cavity | NEOLP | regulation of nucleocytoplasmic transport | 39/2005 | 106/18723 | 1.14e-12 | 2.60e-10 | 39 |
GO:000691331 | Oral cavity | NEOLP | nucleocytoplasmic transport | 75/2005 | 301/18723 | 1.56e-12 | 3.20e-10 | 75 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IFI27 | SNV | Missense_Mutation | novel | c.92N>T | p.Ala31Val | p.A31V | protein_coding | tolerated(0.35) | benign(0.006) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
IFI27 | SNV | Missense_Mutation | rs771278257 | c.344C>T | p.Ala115Val | p.A115V | protein_coding | tolerated(0.1) | benign(0.005) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
IFI27 | SNV | Missense_Mutation | rs755125237 | c.251N>T | p.Ser84Leu | p.S84L | protein_coding | deleterious(0) | benign(0.062) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response | |
IFI27 | SNV | Missense_Mutation | rs534344668 | c.301G>A | p.Gly101Arg | p.G101R | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IFI27 | SNV | Missense_Mutation | novel | c.197N>C | p.Ile66Thr | p.I66T | protein_coding | deleterious(0.02) | benign(0.333) | TCGA-46-6025-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | SD | |
IFI27 | SNV | Missense_Mutation | novel | c.296T>G | p.Leu99Arg | p.L99R | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-51-4079-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3429 | IFI27 | NUCLEAR HORMONE RECEPTOR | TNF-ALPHA | 15086558 | ||
3429 | IFI27 | NUCLEAR HORMONE RECEPTOR | RETINOIDS | 15086558 | ||
3429 | IFI27 | NUCLEAR HORMONE RECEPTOR | VITAMIN D | 15086558 | ||
3429 | IFI27 | NUCLEAR HORMONE RECEPTOR | TGFBETA1 | 15086558 |
Page: 1 |